BrainQ

What BrainQ does

BrainQ (legal name BrainQ Technologies Ltd.) is an Israeli clinical-stage medtech company founded in 2017 by Yotam Drechsler and Prof. Esther Shohami, headquartered in Jerusalem with US operations in Englewood Cliffs, New Jersey. The company is developing the BRAIN.Q Therapeutic System, an AI-powered, non-invasive platform that delivers extremely low-frequency, low-intensity electromagnetic field therapy (ENTF) via a cloud-connected wearable device to support neuroplasticity and recovery in adults with ischemic stroke. AI algorithms analyze EEG brainwave data to derive frequency-tuned stimulation patterns, with sessions administered for approximately 40 minutes per day and supervised through a mobile application with telemedicine integration.

The product is currently investigational in the United States, where BrainQ is conducting the EMAGINE (and follow-on EMAGINE.II) multicenter pivotal trial across leading academic and rehabilitation centers including UCLA, Harvard, Columbia, Cornell, Yale, Kessler Foundation, Brooks Rehabilitation, and MedStar National Rehabilitation Network. The system holds FDA Breakthrough Device Designation, CE marking in the European Union, and AMAR approval in Israel, with limited commercial availability in Chile and Israel, and is most recently extending into a home-based AI brain recovery service launched in February 2026.

The business model centers on prescription-only medical device sales or leasing to hospitals and rehabilitation centers, with secondary streams from remote/monitored therapy sessions (over 2,500 completed to date) and prospective subscription and payer-coverage pathways, including the Medicare Coverage of Innovative Technology (MCIT) pathway enabled by FDA Breakthrough status. The company is venture-backed, having raised over $50 million across a 2018 seed round and a $40 million Series A in August 2021 led by Hanaco Ventures, and currently operates with 11-50 employees.

Name

BrainQ

Legal name

BrainQ Technologies Ltd.

Website

https://brainqtech.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

BrainQ is an Israeli clinical-stage medtech company developing an AI-powered, wearable electromagnetic field therapy platform (ENTF) for ischemic stroke recovery, currently in US pivotal trials with FDA Breakthrough Device Designation.

Ownership category

akta.pro rank

Product category

Neuromodulation Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Offices of Physical, Occupational and Speech Therapists, and Audiologists (62134)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Neurologic Rehabilitation (Stroke, TBI, Parkinson’s, MS) (HSADAIAC)

akta.pro secondary industries

Digital Rehabilitation & Physical Therapy Therapeutics (HLACANAJ), Neurology RPM (epilepsy, Parkinson’s, MS monitoring) (HLALAFAJ), Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

Keywords

• Stroke rehabilitation therapy
• Neuromodulation medical device
• Brain-computer interface
• Electromagnetic field therapy
• AI neurotherapeutics

Headquarters

HQ city

Jerusalem

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Medical Device Sales/Leasing: The BRAIN.Q Therapeutic System is a prescription-only medical device intended for use under supervision of qualified healthcare professionals. Revenue would be generated through device sales or leasing to healthcare facilities and rehabilitation centers.
2. Remote Therapy Sessions: Over 2,500 remote therapy sessions completed demonstrating at-home treatment delivery capability. Virtual care platform enables autonomous therapy delivery with remote clinical oversight, suggesting per-session or subscription-based revenue models for remote monitoring.
3. Healthcare System/Payer Partnerships: Company is working with healthcare systems and payers to ensure the Therapeutic System becomes accessible to stroke patients worldwide through appropriate coverage pathways. FDA Breakthrough Designation provides access to Medicare Coverage of Innovative Technology (MCIT) pathway.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

BrainQ develops the BRAIN.Q Therapeutic System, a prescription-only wearable medical device that delivers AI-powered Electromagnetic Network Targeting Field (ENTF) therapy — extremely low-frequency, low-intensity electromagnetic fields — to support neuroplasticity and recovery in ischemic stroke survivors. The system combines a non-invasive wearable neuromodulation device, a cloud-connected telemedicine platform, and machine learning algorithms trained on EEG brainwave data, and is intended for use under healthcare professional supervision in both clinical and home settings.

Product overview

BRAIN.Q offers a single unified product — the BRAIN.Q Therapeutic System — which is an AI-powered neurotherapeutics platform combining non-invasive neuromodulation via a wearable electromagnetic stimulation device, a mobile application for patient interaction, and a cloud-connected virtual care platform. The system uses AI to analyze brainwave (EEG) data and deliver tailored, frequency-tuned electromagnetic field therapy targeting neural networks for ischemic stroke recovery. The EMAGINE and EMAGINE.II clinical trials are associated research programs testing the therapy in US hospitals. The system is designed for use both in clinical settings and at home.

Differentiator

Problem solved

Functional benefit

Products and services

• BRAIN.Q Therapeutic System An AI-powered neurotherapeutics platform delivering extremely low-frequency, low-intensity electromagnetic fields (ELF-EMF) via a wearable device to support ischemic stroke recovery in both clinical and home settings. The system uses AI-optimized Electromagnetic Network Targeting Field therapy (ENTF) designed to support neuroplasticity by engaging relevant brain networks, combining non-invasive neuromodulation, evidence-based exercises, and remote clinical oversight within a single scalable platform. Intended for adult ischemic stroke survivors aged 22–80 under supervision of qualified healthcare professionals.
• BRAIN.Q Home-Based AI Brain Recovery Service A home-based AI brain recovery service that delivers brain rehabilitation at home through AI technology, providing the BRAIN.Q therapeutic experience in a remote, at-home setting.

Quantifiable outcome

• 77% of treatment group achieved mRS scores of 0 or 1 (no symptoms or minor symptoms with no significant disability) vs 25% in sham group
• +6 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Novocure: Novocure develops Tumor Treating Fields (TTFields), a non-invasive electromagnetic field therapy platform for cancer and other conditions. Most direct peer to BrainQ's electromagnetic field-based neuromodulation approach, with overlapping board representation (Eilon Kirson, ex-Novocure CSO, sits on BrainQ's board).
• Neuronetics: Neuronetics develops transcranial magnetic stimulation (TMS) systems, primarily NeuroStar, for depression and other neurological/psychiatric indications. Direct competitor in non-invasive clinical neuromodulation targeting brain networks, with FDA-cleared device and established commercial channel.
• Brainsway: Brainsway develops deep transcranial magnetic stimulation (Deep TMS) systems for depression, OCD, smoking cessation, and other neurological/psychiatric indications. Comparable non-invasive neuromodulation device company targeting brain network modulation with regulatory clearances in multiple geographies.
• Nexstim: Nexstim develops navigated transcranial magnetic stimulation (nTMS) systems for both therapeutic (depression, chronic pain) and diagnostic (pre-surgical mapping) applications. Closely comparable in non-invasive brain stimulation modality and clinical use-case profile.
• Magstim: Magstim is a pioneer in transcranial magnetic stimulation (TMS) technology, providing devices for clinical neuroscience research and therapeutic applications. Comparable as an established non-invasive electromagnetic brain stimulation device company.
• electroCore: electroCore develops non-invasive vagus nerve stimulation (nVNS) devices such as gammaCore for migraine, cluster headache, and other neurological conditions. Comparable non-invasive, non-pharmacologic neuromodulation device company targeting neurological disorders.

Emerging players

• Saluda Medical: Saluda Medical develops closed-loop spinal cord stimulation systems for chronic pain and is exploring applications in neurological recovery. Emerging peer in the neuromodulation device space with comparable R&D intensity and clinical-stage profile.

Broad incumbents

• Penumbra: Penumbra is a leading interventional thrombectomy device company for acute ischemic stroke, with a broader neurovascular portfolio. Broad incumbent addressing the same stroke patient population, though in acute rather than recovery-stage care.
• MicroPort Scientific: MicroPort operates a neurovascular business offering stroke intervention and access devices. Broad incumbent in stroke care with overlapping customer base (hospitals, neurologists, neurointerventionalists) though focused on acute intervention rather than post-stroke recovery.

Regional players

• Saol International: Saol is developing rEVOlution Therapeutics' investigational stroke recovery therapy (PMC-403, an intranasal drug/device combination). Comparable regional clinical-stage peer focused on stroke recovery, though via pharmacological rather than electromagnetic means.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/brainq-technologies
• Xx.com/BrainQTech
• Facebookfacebook.com/BrainQTech

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds2 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BrainQ